Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: Rescue with intravenous immunoglobulin therapy

Journal of Clinical Rheumatology

Volumn 9, Issue 4, 2003, Pages 253-258

  Tristano, Antonio G ^a   Casanova Escalona, Lady ^b   Torres, Alcira ^b   Rodríguez, Martín A ^b,c  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^b Centro Medico Dr Rafael Guerra Mendez   (Venezuela)

^c POBA International   (United States)

Author keywords

Intravenous immunoglobulins; Macrophage activation syndrome; Still disease

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CASE REPORT; CELL PROLIFERATION; CHILD; DRUG EFFECT; HUMAN; HYPOVOLEMIA; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION; MALE; ONSET AGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REMISSION; RISK BENEFIT ANALYSIS;

EID: 0042574161     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000081259.61370.eb     Document Type: Article

References (29)

1. Grom A, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630-632.
2. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421-426.
3. Prieur AM, Stephan JL. Macrophage activation syndrome in children with joint diseases. Rev Rheum Engl Ed. 1994;61:385-388.
4. Morris JA, Adamson AR, Holt PJL, et al. Still's disease and the virus-associated haemophagocytic syndrome. Ann Rheum Dis. 1985;44:349-353.
5. Stephan JL, Kone-Paut I, Galambrun C, et al. Reactive hemophagocytic syndrome in children with inflamatoy disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285-1292.
6. Ravelli A, De Benedetti F, Viola S, et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128:275-278.
7. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile rheumatoid arthritis: report of five cases. J Pediatr. 1996;129: 750-754.
8. Stephan JL, Séller J, Hubert P, et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11:451-456.
9. McPeake JR, Hirst WJ, Brind AM, et al. Hepatitis A causing a second episode of virus-associated haemophagocytic lymphohistiocytosis in a patient with Still's disease. J Med Virol. 1993;39:173-175.
10. Heaton DC, Moller PW. Still's disease associated with Coxsackie infection and haemophagocytic syndrome. Ann Rheum Dis. 1985;44:341-344.
11. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemaphagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 1979;44:993-902.
12. Schwartz D, Averbuch M, Pines A, et al. Disseminated intravascular coagulation with renal and liver damage as the predominant manifestations of recurrent relapses in systemic juvenile rheumatoid arthritis. Ann Rheum Dis. 1992;51:347-349.
13. Barah J, Cooper M, Tauber Z. Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9:541-543.
14. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drug or infection. J Pediatr. 1985;106:561-566.
15. Mukamel M, Bernstein BH, Brik R, et al. The prevalence of coagulation abnormalities in juvenile rheumatoid arthritis. J Rheumatol. 1987;14:1147-1149.
16. Silverman ED, Miller JJ, Bernstein B, et al. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr. 1983;103: 872-876.
17. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986; 83:4533-4537.
18. Van der Pol T, Buller HR, Cate HT, et al. Activation of coagulation after administration of TNF to normal subjects. N Engl J Med. 1990;23:1622-1627.
19. Prahalad S, Bove KE, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120-2124.
20. Henter J, Elinder G, Soder O, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78:18-22.
21. Longo G, Luppi M, Bertesi M, et al. Still's disease, severe thrombocytopenia, and acute hepatitis associated with acute parvovirus B19 infection. Clin Infect Dis. 1998;26:994-995.
22. Ravelli A, Caria MC, Buratti S, et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:865-867.
23. Stephan KJ, Donadieu J, Le Deist F, Blanche S, et al. Treatment of familial hemophagocytic lymphohistiocytosis with anti-thymocyte globulins, steroids and cyclosporin A. Blood. 1993;82:2319-2323.
24. Imashuku S, Teramura T, Morimoto A, et al. Recent developments in the management of haemophagocytic lymphohistiocytosis. Expert Opin Pharmacother. 2001;2:1437-1448.
25. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo control trial. J Rheumatol. 1994;21:2353-2358.
26. Uziel Y, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study. J Rheumatol. 1996;23:910-918.
27. Achiron A, Margalit R, Hershkoviz R, et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor α secretion. J Clin Invest. 1994;93:600-605.
28. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
29. Ono M, Bolland S, Tempts P, Ravetch JV. Role of inositol phosphate SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature. 1996;383:263-267.